Alterity Therapeutics Limited
ATH.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$58.45M
Close$
Share Statistics
| Market cap | $58.45 Million |
|---|---|
| Enterprise Value | $21.32 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -74.85% |
|---|---|
| Return on Assets | -69.49% |
| Return on Invested Capital | -91.65% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.6 |
| Enterprise Value to EBIT | -0.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alterity Therapeutics Ltd
11 employees
CEO: Geoffrey Kempler Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among oth...